Breast cancer liver metastasis is one of the most common distant metastatic sites for breast cancer (bone, lung, and liver). Imaging features vary by breast cancer subtype: luminal types are usually hypovascular, HER2-positive and triple-negative types may be more hypervascular. Typically, hypovascular pattern with rim enhancement + peripheral washout in portal venous phase is dominant. Calcification and capsular retraction may develop in treated metastases. Liver involvement in metastatic breast cancer significantly affects prognosis.
Age Range
35-75
Peak Age
55
Gender
Female predominant
Prevalence
Common
Breast cancer cells reach the liver hematogenously (systemic venous drainage → hepatic artery or portal vein). Liver metastasis is usually part of widespread disease (along with bone, lung, brain). Metastatic pattern differs by breast cancer subtype: (1) Luminal type (ER+/PR+) — hypovascular, slow-growing, may contain fibrous stroma, shows rim enhancement. (2) HER2+ — more aggressive, may be hypervascular, good treatment response (trastuzumab). (3) Triple-negative — most aggressive, heterogeneous enhancement, necrosis common, no targeted therapy beyond chemotherapy. In hypovascular metastases, tumor cells proliferate in portal sinusoids and suppress portal venous supply — appear dark (hypodense) compared to surroundings in portal venous phase. Rim enhancement reflects the distinction between peripheral viable tumor tissue and central necrosis.
The combination of thin peripheral rim enhancement + hypointense/hypodense central necrotic area in portal venous phase creates the 'target' or 'bull's eye' appearance. This pattern is the most diagnostic enhancement finding of hypovascular metastases (colorectal, breast, lung). The peripheral rim reflects limited vascularity of viable tumor cells, the central area reflects tumor necrosis. In hepatobiliary phase, these lesions remain completely dark — creating maximum contrast with normal parenchyma.
Multiple hypodense lesions compared to surrounding parenchyma in portal venous phase. Thin rim enhancement at lesion periphery and non-enhancing center is the typical finding. This 'target' or 'bull's eye' pattern is the most common enhancement pattern of hypovascular metastases.
Report Sentence
Multiple lesions hypodense compared to surrounding parenchyma are observed in the liver in portal venous phase, with rim enhancement and central necrotic areas consistent with metastasis.
Enhancement in arterial phase varies by breast cancer subtype. Luminal type: weak or absent (hypovascular). HER2+ and triple-negative: rim or homogeneous enhancement may be seen (mixed vascularity). Peripheral enhancement + central necrosis in large lesions.
Report Sentence
The lesions demonstrate variable enhancement in arterial phase, with vascularity differences attributed to breast cancer subtype.
Mild to moderate hyperintense signal on T2-weighted images. In large lesions, peripheral moderate hyperintensity (viable tumor) + central more hyperintense area (necrosis/liquefaction) or hypointense area (fibrosis) — 'target sign'. Not as bright as hemangioma.
Report Sentence
The lesions demonstrate mild to moderate hyperintense signal on T2-weighted sequences, with 'target sign' observed in some lesions.
Prominent diffusion restriction on DWI (hyperintensity + low ADC). Most sensitive MR sequence for metastasis detection. Small metastases (<1 cm) detected on DWI may be missed on other sequences. In treatment response monitoring, ADC increase indicates treatment response.
Report Sentence
Prominent diffusion restriction is observed in the lesions on DWI sequences, consistent with metastatic involvement.
All metastases appear hypointense on hepatobiliary phase (gadoxetic acid). Metastasis cells are not hepatocytes — they do not express OATP transporters. This phase provides the highest contrast-to-noise ratio for detection of small metastases.
Report Sentence
Multiple lesions markedly hypointense compared to surrounding parenchyma are observed on hepatobiliary phase, confirming metastatic involvement.
Criteria
Estrogen and/or progesterone receptor positive. Metastasis of the most common breast cancer subtype.
Distinct Features
Hypovascular pattern dominant. Slow growth. May respond to hormonal therapy. Post-treatment calcification may develop. Bone metastasis more common.
Criteria
HER2 overexpression. Eligible for trastuzumab targeted therapy.
Distinct Features
Mixed vascularity (may be hypovascular or hypervascular). Dramatic response to treatment (size reduction, decreased enhancement). High risk of brain metastasis.
Criteria
ER/PR/HER2 negative. Metastasis of the most aggressive subtype.
Distinct Features
Rapid growth, necrosis common. Heterogeneous enhancement. Limited targeted therapy beyond chemotherapy (immunotherapy being investigated). Visceral metastasis dominant (bone less common).
Distinguishing Feature
Hemangioma is very bright on T2 ('light bulb sign'), metastasis is mild-moderate hyperintense. Hemangioma shows peripheral nodular (globular) enhancement + centripetal filling — metastasis shows rim enhancement (thin). Hemangioma loses signal on DWI at high b-values ('T2 shine-through'), metastasis shows true diffusion restriction.
Distinguishing Feature
Simple cyst does not enhance in any phase, water density (0-20 HU), no rim enhancement. Very bright on T2 (isointense to CSF). Metastasis shows rim enhancement and is higher than water density.
Distinguishing Feature
ICC is usually a solitary large mass, breast metastasis is multiple. ICC shows capsular retraction + bile duct dilatation. ICC shows centripetal filling, breast metastasis shows rim enhancement. Primary malignancy history is distinguishing.
Distinguishing Feature
Hepatic lymphoma shows homogeneous hypodense lesions, rim enhancement is rare. Very prominent diffusion restriction on DWI (ADC very low). Splenomegaly and retroperitoneal lymphadenopathy are common. B symptoms (fever, night sweats, weight loss) are distinguishing.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
3-monthTreatment of breast cancer liver metastasis is determined by receptor status of primary tumor: ER+/PR+ → hormonal therapy (tamoxifen, aromatase inhibitors) + CDK4/6 inhibitors (palbociclib, ribociclib); HER2+ → trastuzumab/pertuzumab + chemotherapy or T-DXd (trastuzumab deruxtecan); Triple-negative → chemotherapy (taxanes, platinum) ± immunotherapy (pembrolizumab — if PD-L1 positive). Biopsy from liver metastasis is recommended as receptor status may change (ER loss or HER2 gain). Treatment response is evaluated by CT/MR at 3-month intervals according to RECIST 1.1 criteria. In oligometastatic disease, local therapies (stereotactic radiotherapy, RFA, hepatic resection) may be considered.
Liver metastasis indicates metastatic disease (stage IV) in breast cancer. Systemic chemotherapy and targeted therapy (trastuzumab, CDK4/6 inhibitors) are the primary treatment approach. Local treatment (ablation, stereotactic RT) may be considered in oligometastatic disease.